PriceTargets.com logo

Assura - AGR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 47.48 As of 10/3/2025 12:50 PM ET
▲ +0.18 (0.38%)

This chart shows the closing price for AGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Assura Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGR

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Assura in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 47.48.

This chart shows the closing price for AGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Assura. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/1/2025Shore Capital GroupReiterated RatingHold
9/30/2025Peel HuntReiterated RatingBuyGBX 60
9/17/2024Berenberg BankReiterated RatingBuyGBX 51
8/13/2024Shore Capital GroupReiterated RatingHold
7/4/2024Shore Capital GroupReiterated RatingHold
5/21/2024Shore Capital GroupReiterated RatingBuy
3/20/2024Peel HuntDowngradeAddGBX 48
2/9/2024BarclaysReiterated RatingOverweightGBX 53
11/20/2023Berenberg BankBoost TargetBuyGBX 49 ➝ GBX 51
11/17/2023BarclaysBoost TargetOverweightGBX 52 ➝ GBX 53
11/16/2023Shore Capital GroupInitiated CoverageBuy
7/6/2023Shore Capital GroupReiterated RatingBuy
5/24/2023JPMorgan Chase & Co.Reiterated RatingNeutralGBX 56
5/24/2023BarclaysReiterated RatingOverweightGBX 57
5/23/2023Peel HuntReiterated RatingBuyGBX 65
5/23/2023Shore Capital GroupReiterated RatingBuy
1/18/2023JPMorgan Chase & Co.Lower TargetNeutralGBX 62 ➝ GBX 56
1/17/2023BarclaysReiterated RatingBuyGBX 60
12/1/2022BarclaysLower TargetOverweightGBX 73 ➝ GBX 60
12/1/2022Berenberg BankLower TargetHoldGBX 75 ➝ GBX 65
11/23/2022Shore Capital GroupReiterated RatingBuy
8/31/2022Berenberg BankLower TargetHoldGBX 80 ➝ GBX 75
7/14/2022Shore Capital GroupReiterated RatingBuy
7/6/2022Shore Capital GroupReiterated RatingBuy
7/4/2022BarclaysLower TargetOverweightGBX 80 ➝ GBX 73
5/31/2022Berenberg BankReiterated RatingHoldGBX 80
5/25/2022JPMorgan Chase & Co.Reiterated RatingOverweightGBX 79
5/24/2022Peel HuntReiterated RatingAddGBX 85
5/24/2022Shore Capital GroupReiterated RatingBuy
5/23/2022BarclaysReiterated RatingOverweightGBX 80
5/9/2022BarclaysReiterated RatingOverweightGBX 80
4/29/2022BarclaysReiterated RatingOverweightGBX 80
4/19/2022BarclaysReiterated RatingOverweightGBX 80
4/13/2022Berenberg BankReiterated RatingHoldGBX 80
4/5/2022BarclaysReiterated RatingOverweightGBX 80
4/1/2022Shore Capital GroupReiterated RatingBuy
3/21/2022BarclaysReiterated RatingOverweightGBX 80
3/16/2022Shore Capital GroupReiterated RatingBuy
3/8/2022BarclaysReiterated RatingOverweightGBX 87
3/1/2022Shore Capital GroupReiterated RatingBuy
2/14/2022BarclaysReiterated RatingOverweightGBX 87
1/31/2022BarclaysReiterated RatingOverweightGBX 87
12/8/2021Liberum CapitalLower TargetHoldGBX 77 ➝ GBX 70
12/1/2021JPMorgan Chase & Co.Reiterated RatingNeutralGBX 79
11/30/2021BarclaysReiterated RatingOverweightGBX 87
11/30/2021Shore Capital GroupReiterated RatingCoverage Pending
11/24/2021Liberum CapitalReiterated RatingHold
11/11/2021Berenberg BankReiterated RatingOverweightGBX 87
11/11/2021Shore Capital GroupReiterated RatingCoverage Pending
11/11/2021Liberum CapitalReiterated RatingHoldGBX 77
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2026

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Assura logo
Assura plc is a specialist healthcare property investor and developer. We enable better health outcomes through our portfolio of more than 600 healthcare buildings across the UK and Ireland, from which over six million patients are served. We BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G). Assura plc achieved B Corp certification in July 2024 - the first FTSE 250 business to do so.
Read More

Today's Range

Now: GBX 47.48
Low: 46.76
High: 48.50

50 Day Range

MA: GBX 47.48
Low: 47.48
High: 47.48

52 Week Range

Now: GBX 47.48
Low: 35.24
High: 50.95

Volume

288,991 shs

Average Volume

25,004,627 shs

Market Capitalization

£1.54 billion

P/E Ratio

895.85

Dividend Yield

7.10%

Beta

0.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Assura?

The following Wall Street sell-side analysts have issued stock ratings on Assura in the last twelve months:
View the latest analyst ratings for AGR.

What is the current price target for Assura?

0 Wall Street analysts have set twelve-month price targets for Assura in the last year. has the lowest price target set, forecasting a price of £100,000 for Assura in the next year.
View the latest price targets for AGR.

What is the current consensus analyst rating for Assura?

Assura currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AGR.

What other companies compete with Assura?

Other companies that are similar to Assura include Primary Health Properties, Target Healthcare REIT, Impact Healthcare REIT, Life Science REIT and Medicx Fund. Learn More about companies similar to Assura.

How do I contact Assura's investor relations team?

Assura's physical mailing address is The Brew House, Greenalls Avenue, WARRINGTON, WA4 6HL, United Kingdom. The real estate investment trust's listed phone number is +44-1925-420660. The official website for Assura is www.assuraplc.com. Learn More about contacing Assura investor relations.